Please provide your email address to receive an email when new articles are posted on . Serum HBV RNA declines at 1 and 2 years were independently associated with risk for HCC. Patients with less ...
Chronic hepatitis B virus (HBV) infection remains a major cause of liver diseases, including cirrhosis and hepatocellular carcinoma. Reliable biomarkers for assessing viral replication, liver damage, ...
The rate of functional cure (HBsAg loss) remains unsatisfactory following pegylated interferon (PEG-IFN) treatment in chronic hepatitis B. To optimize PEG-IFN administration, this study aimed to ...
ABI-4334 shows strong antiviral activity and favorable safety in Phase 1b study for chronic HBV, with data expected in 2025. ABI-4334 demonstrated strong antiviral activity with a mean reduction of ...
In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...
PARIS — People with HIV and resolved HBV infection who switched from tenofovir-based antiretroviral therapy (ART) to tenofovir-sparing regimens did not see clinically meaningful hepatitis B virus (HBV ...
Previous studies have found that the effectiveness of vaccines can be increased with the knockdown of HBsAg using a small interfering RNA (siRNA). The efficacy of a bivalent mRNA vaccine in ...
Please provide your email address to receive an email when new articles are posted on . The FDA’s recent authorization of a rapid, point-of-care test to diagnose current hepatitis C virus infection is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results